Wordt geladen...
Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study
NVA237 (glycopyrronium bromide) is a once-daily long-acting muscarinic antagonist (LAMA) in development for chronic obstructive pulmonary disease (COPD). The GLycopyrronium bromide in COPD airWays clinical Study 2 (GLOW2) evaluated the efficacy and safety of NVA237 in moderate-to-severe COPD over 52...
Bewaard in:
| Hoofdauteurs: | , , , , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
European Respiratory Society
2012
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3485572/ https://ncbi.nlm.nih.gov/pubmed/23060624 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1183/09031936.00040712 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|